COVID Vaccine Developer/Manufacturer Announcements [organizations from WHO EUL/PQ listing above]

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer/Manufacturer Announcements [organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

Bharat Biotech, India
Press Releases – Website not responding at inquiry

BioCubaFarma – Cuba
Últimas Noticias – No new digest announcements identified

 

CanSinoBIO
News – No new digest announcements identified

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News
May 13, 2021
Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
May 13, 2021
:: Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK
:: CV2CoV mRNA shows high levels of antigen production in rat model
:: Fast onset of strong neutralizing antibody titers after first vaccination
:: High cross-neutralizing capacity of induced antibodies against selected Variants of Concern

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases
May 12, 2021
Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine

 

Novavax
Press Releases
Novavax Statement on Updated PREVENT-19 Trial Protocol
Statement = COVID-19
5/10/2021
An updated protocol version 8.0 for our PREVENT-19 Phase 3 clinical trial (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial) was posted to the Novavax website today. PREVENT-19 is a randomized, observer-blinded, placebo-controlled study evaluating the efficacy, safety, and immunogenicity of NVX-CoV2373 with Matrix-M™ adjuvant in up to 30,000 subjects 18 years of age and older compared with placebo. The company’s pivotal Phase 3 study in the U.S. and Mexico began in December 2020 and significant progress has been made to-date, with final data expected in the second quarter of 2021…

Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
5/10/2021
– Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus
– Data shared via preprint server for biology, bioRxiv, ahead of publication…A pre-print of the manuscript is available at bioRxiv.org.

 

Pfizer
Recent Press Releases
05.10.2021
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
:: In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
:: Data also submitted to European Medicines Agency (EMA) and other global regulators, with additional authorizations expected in coming weeks

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]